Latest Content

Dexamethasone before Yescarta reduced the severity of ICANS but did not change how often ICANS or CRS occurred in patients with LBCL.

Pelabresib plus Jakafi delivered stronger, clinically meaningful benefits versus Jakafi alone for people with untreated myelofibrosis.

Tecvayli plus Darzalex Faspro improved overall and progression-free survival versus standard daratumumab regimens in relapsed/refractory multiple myeloma.

Jaypirca therapy improved progression-free survival versus bendamustine plus Rituxan a phase 3 trial for untreated CLL/SLL.

In a recent interview with CURE, Dr. Kai Tsao discussed treatment advancements for patients with prostate cancer.

Lore Gruenbaum, chief scientific officer of Blood Cancer United, sat down for an interview with CURE to discuss the themes shaping blood cancer care today.

Dr. Josh Brody discussed key clinical trial findings for patients with diffuse large B-cell lymphoma.

Zervyteg improved responses and was safe in steroid- and Jakafi-resistant acute graft-versus-host disease affecting the GI tract in a phase 3 trial.

In a direct comparison, Jaypirca matched Imbruvica in response and suggested a progression-free survival benefit for patients with CLL/SLL.

A clinical trial found that Jaypirca was more effective than Imbruvica across the frontline and relapsed/refractory CLL/SLL settings.

The phase 3 EPCORE FL-1 trial showed that adding Epkinly to Rituxan and Revlimid delivered superior PFS and response rates.

A new combination of Blincyto and Iclusig provided improved results and stronger responses for patients with Philadelphia chromosome-positive ALL compared with traditional chemotherapy.